{
  "@context": {
    "bsc": "http://bioschemas.org/",
    "edam": "http://edamontology.org/",
    "rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
    "rdfs": "http://www.w3.org/2000/01/rdf-schema#",
    "sc": "http://schema.org/",
    "xsd": "http://www.w3.org/2001/XMLSchema#"
  },
  "@graph": [
    {
      "@id": "https://doi.org/10.1016/J.PHRS.2019.104444",
      "@type": "sc:CreativeWork"
    },
    {
      "@id": "https://bio.tools/MANTA_autogenerated",
      "@type": "sc:SoftwareApplication",
      "sc:applicationSubCategory": [
        {
          "@id": "edam:topic_3070"
        },
        {
          "@id": "edam:topic_3335"
        }
      ],
      "sc:citation": [
        {
          "@id": "https://doi.org/10.1016/J.PHRS.2019.104444"
        },
        "pubmed:31493513"
      ],
      "sc:description": "> MEDIUM CONFIDENCE! | > HOMEPAGE MISSING! | > NAME (MANTA) SIMILAR TO (PUB. DIFFERENT) bio.tools/manta_sv (Manta), bio.tools/manta (manta) | > CORRECT NAME OF TOOL COULD ALSO BE 'Maastricht Antiarrhythmic Drug Evaluator', 'AADs' | A computational tool for better understanding of antiarrhythmic drugs | Cardiac arrhythmias are a global health burden, contributing significantly to morbidity and mortality worldwide. Despite technological advances in catheter ablation therapy, antiarrhythmic drugs (AADs) remain a cornerstone for the management of cardiac arrhythmias. Experimental and translational studies have shown that commonly used AADs exert multiple effects in the heart, the manifestation of which strongly depends on the exact experimental or clinical conditions. This diversity makes the optimal clinical application of AADs challenging",
      "sc:name": "MANTA_autogenerated",
      "sc:url": "https://www.ncbi.nlm.nih.gov/pubmed/?term=31493513"
    }
  ]
}